Cormorant Asset Management

Portfolio Co Investors 2026 for Cormorant Asset Management: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Cormorant Asset Management accounts for 62 tracked companies with verified cap-table data, 62 of which disclose round sizes totalling $12B. The median disclosed raise is $157M, and the largest is Autolus at $1.2B, ahead of Spyre Therapeutics ($644M) and Alumis ($529M).

The names that recur most often on these co-invested cap tables are Cormorant Asset Management (62 companies), Logos Capital (17 companies), Janus Henderson Investors (15 companies), Surveyor Capital (14 companies), OrbiMed (12 companies), Vivo Capital (10 companies). By latest disclosed round, the market skews Series B (20), Series C (15), Series A (11), Growth (7).

Best funded Cormorant Asset Management companies

  1. Autolus — $1.2B (latest: IPO)
  2. Spyre Therapeutics — $644M (latest: Growth)
  3. Alumis — $529M (latest: Series C)
  4. Edgewise Therapeutics — $495M (latest: Growth)
  5. Talaris Therapeutics — $365M (latest: Other Equity)
  6. Axon Neurosciences — $340M (latest: Series C)
  7. Aspen Neuroscience — $340M (latest: Series C)
  8. Viela Bio — $300M (latest: Series B)
  9. Greenlight Biosciences — $277M (latest: Series C)
  10. Triveni Bio — $277M (latest: Series C)
  11. NiKang Therapeutics — $260M (latest: Series C)
  12. Enliven Therapeutics — $230M (latest: Growth)
  13. Supira Medical — $225M (latest: Series E)
  14. Aligos Therapeutics — $225M (latest: Series B)
  15. OnKure Therapeutics — $222M (latest: Growth)

Cormorant Asset Management, LP — related firms and companies (56)

Cormorant Asset Management, LP profile · All research reports